Results 201 to 210 of about 510,668 (221)

Cardio-Oncology

2020
Devinder S. Dhindsa, Anant Mandawat
  +4 more sources

Hypertension in the Cardio-Oncology Clinic

Heart Failure Clinics, 2019
As cancer therapies improve, the population of survivors of cancer has increased, and the long-term effects of cancer treatments have become more apparent. Cardiotoxicity is a well-established adverse effect of many antineoplastic agents. Hypertension is common in survivors of cancer, can be caused or worsened by certain agents, and has been shown to ...
Lauren J, Hassen, Daniel J, Lenihan, Ragavendra R, Baliga   +2 more
openaire   +2 more sources

Cardio-oncological management of patients

Seminars in Oncology, 2019
Session III of the Second International Colloquium on Cardio-Oncology focused on the diagnosis, management, and prevention of cardiovascular toxicity of cancer drugs. With a large menu of biomarkers and imaging modalities available to the cardio oncologist, there continues to be no consensus regarding the best use of each modality alone and in ...
Cardinale, Daniela M, Barac, Ana, Torbicki, Adam, Khandheria, Bijoy K, Lenihan, Daniel, Minotti, Giorgio   +5 more
openaire   +3 more sources

Pediatric Cardio-oncology

2023
Alexander Raskin, Thomas D. Ryan
openaire   +1 more source

Year in cardiovascular medicine: cardio-oncology 2020-21.

European Heart Journal, 2022
Teresa López-Fernández
exaly  

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

European Heart Journal, 2022
Iris Parrini, Thomas Suter, Fuad Samadov
exaly  

Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement

Ca-A Cancer Journal for Clinicians, 2020
Joshua D. Mitchell
exaly  

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

European Journal of Heart Failure, 2020
Javid J. Moslehi, Frank Ruschitzka, Carlo Gabriele Tocchetti   +2 more
exaly  

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

European Heart Journal, 2022
Kathryn J Ruddy, Peter Valent
exaly  

Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease

Journal of the American Heart Association, 2020
Javid J. Moslehi, Joseph Pierre Aboumsallem   +1 more
exaly